Prolactin inhibits BCL6 expression in breast cancer through a stat5a-dependent mechanism

Thai H. Tran, Fransiscus E. Utama, Justin Lin, Ning Yang, Ashley B. Sjolund, Amy Ryder, Kevin J. Johnson, Lynn M. Neilson, Chengbao Liu, Kristin L. Brill, Anne L. Rosenberg, Agnieszka K. Witkiewicz, Hallgeir Rui

Research output: Contribution to journalArticlepeer-review

60 Scopus citations


BCL6 is a transcriptional repressor that recognizes DNA target sequences similar to those recognized by signal transducer and activator of transcriptions 5 (Stat5). BCL6 disrupts differentiation of breast epithelia, is downregulated during lactation, and is upregulated in poorly differentiated breast cancer. In contrast, Stat5a mediates prolactin-induced differentiation of mammary epithelia, and loss of Stat5 signaling in human breast cancer is associated with undifferentiated histology and poor prognosis. Here, we identify the mammary cell growth factor prolactin as a potent suppressor of BCL6 protein expression in human breast cancer through a mechanism that requires Stat5a, but not prolactin-activated Stat5b, MEK-ERK, or PI3KAKT pathways. Prolactin rapidly suppressed BCL6 mRNA in T47D, MCF7, ZR75.1, and SKBr3 breast cancer cell lines, followed by prolonged reduction of BCL6 protein levels within 3 hours. Prolactin suppression of BCL6 was enhanced by overexpression of Stat5a but not Stat5b, was mimicked by constitutively active Stat5a, but did not require the transactivation domain of Stat5a. Stat5 chromatin immunoprecipitation demonstrated physical interaction with a BCL6 gene regulatory region, and BCL6 transcript repression required histone deacetylase activity based on sensitivity to trichostatin A. Functionally, BCL6 overexpression disrupted prolactin induction of Stat5 reporter genes. Prolactin suppression of BCL6 was extended to xenotransplant tumors in nude mice in vivo and to freshly isolated human breast cancer explants ex vivo. Quantitative immunohistochemistry revealed elevated BCL6 in high-grade and metastatic breast cancer compared with ductal carcinoma in situ and nonmalignant breast, and cellular BCL6 protein levels correlated negatively with nuclear Stat5a (r = -0.52; P < 0.001) but not with Stat5b. Loss of prolactin-Stat5a signaling and concomitant upregulation of BCL6 may represent a regulatory switch facilitating undifferentiated histology and poor prognosis of breast cancer.

Original languageEnglish (US)
Pages (from-to)1711-1721
Number of pages11
JournalCancer research
Issue number4
StatePublished - Feb 15 2010

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Prolactin inhibits BCL6 expression in breast cancer through a stat5a-dependent mechanism'. Together they form a unique fingerprint.

Cite this